
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
By the time you read this, the war in Iraq will be largely over, and members of Congress returning from their Spring break may be able to turn their attention to the general welfare.






